

9. The method of claim 8, wherein the qRT-PCR comprises a probe consisting of 5'→3' sequence CGCATGGGGTTTCGGCTTCCTGTCC (SEQ ID NO: 14), a primer consisting of 5'→3' sequence CACGGTGCGGGCATCTG (SEQ ID NO: 15), and a primer consisting of 5'→3' sequence CCTTCCATGTGCAGCTTACTC (SEQ ID NO: 16)

10. The method of any one of claims 1 to 9, wherein the marker expression is normalised.

11. The method of claim 10, wherein the marker expression is normalised to GAPDH expression.

12. The method of any one of claims 1 to 11, wherein the known proportion is 0.001%.

13. The method of any one of claims 1 to 12, wherein the PSCs are iPSCs.

14. The method of any one of claims 1 to 13, wherein the cells are MSCs.

15. The method of claim 14, wherein the MSCs are cultured in E8 Complete Medium.

16. The method according to any one of claims 1 to 15 further comprising formulating into a therapeutic composition the culture of cells in which residual, undifferentiated PSCs are absent or lower than a known proportion.

17. A method for manufacturing a therapeutic composition, the method comprising formulating into a composition for therapeutic administration to a subject a culture of cells in which residual, undifferentiated PSCs are absent or lower than a known proportion when detected by the method of any one of claims 1 to 15.

18. Use of a culture of cells in which residual, undifferentiated PSCs are absent or lower than a known proportion in the manufacture of a medicament for treating or preventing a condition in a subject, wherein residual, undifferentiated PSCs in the culture of cells differentiated from PSCs are detected by the method of any one of claims 1 to 15.

19. The use of claim 18, wherein the condition is selected from bone cysts, bone neoplasms, fractures, cartilage defects, osteoarthritis, ligament injury, osteogenesis imperfecta, osteonecrosis, osteoporosis, aplastic anaemia, graft versus host disease (GvHD), myelodysplastic syndrome, Type 1 diabetes, Type 2 diabetes, autoimmune hepatitis, liver cirrhosis, liver failure,

dilated cardiomyopathy, heart failure, myocardial infarction, myocardial ischemia, Crohn's disease, ulcerative colitis, burns, epidermolysis bullosa, lupus erythematosus, rheumatoid arthritis, Sjogren's disease, systemic sclerosis, bronchopulmonary dysplasia, chronic obstructive airways disease, emphysema, pulmonary fibrosis, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, brain injury, ataxia, degenerative disc disease, multiple system atrophy, multiple sclerosis, Parkinson's disease, retinitis pigmentosa, Romberg's disease, spinal cord injury, stroke, muscular dystrophy, limb ischaemia, kidney injury, lupus nephritis, endometriosis and complications of bone marrow or solid organ transplantation.

20. A kit for detecting residual, undifferentiated PSCs in a culture of cells differentiated from PSCs, the kit comprising:

laminin-521; and

E-cadherin; and

a ROCK inhibitor.

21. The kit of claim 20, further comprising PCR primers and optionally a PCR probe for quantitating in the cultured cells expression of a marker of residual, undifferentiated PSCs.

22. The kit of claim 20 or claim 21, further comprising a medium, optionally comprising the ROCK inhibitor.

23. The kit of any one of claims 20 to 22, further comprising a substrate, optionally coated with the laminin-521 and E-cadherin.